Belgium · Delayed Price · Currency is EUR Onward Medical Statistics
Total Valuation
Onward Medical has a market cap or net worth of EUR 201.29 million. The enterprise value is 133.57 million.
| Market Cap | 201.29M |
| Enterprise Value | 133.57M |
Important Dates
The last earnings date was Wednesday, September 9, 2026.
| Earnings Date | Sep 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Onward Medical has 69.53 million shares outstanding. The number of shares has increased by 8.02% in one year.
| Current Share Class | 69.53M |
| Shares Outstanding | 69.53M |
| Shares Change (YoY) | +8.02% |
| Shares Change (QoQ) | +20.17% |
| Owned by Insiders (%) | 1.06% |
| Owned by Institutions (%) | 18.85% |
| Float | 54.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 23.90 |
| PB Ratio | 2.80 |
| P/TBV Ratio | 3.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.23, with a Debt / Equity ratio of 0.19.
| Current Ratio | 9.23 |
| Quick Ratio | 8.60 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.30 |
| Interest Coverage | -20.33 |
Financial Efficiency
Return on equity (ROE) is -90.85% and return on invested capital (ROIC) is -43.04%.
| Return on Equity (ROE) | -90.85% |
| Return on Assets (ROA) | -35.30% |
| Return on Invested Capital (ROIC) | -43.04% |
| Return on Capital Employed (ROCE) | -48.88% |
| Weighted Average Cost of Capital (WACC) | 9.17% |
| Revenue Per Employee | 61,467 |
| Profits Per Employee | -330,445 |
| Employee Count | 137 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 2.52 |
Taxes
In the past 12 months, Onward Medical has paid 442,000 in taxes.
| Income Tax | 442,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.79% in the last 52 weeks. The beta is 0.85, so Onward Medical's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | -43.79% |
| 50-Day Moving Average | 2.47 |
| 200-Day Moving Average | 3.23 |
| Relative Strength Index (RSI) | 73.40 |
| Average Volume (20 Days) | 211,233 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Onward Medical had revenue of EUR 8.42 million and -45.27 million in losses. Loss per share was -0.85.
| Revenue | 8.42M |
| Gross Profit | 6.35M |
| Operating Income | -44.25M |
| Pretax Income | -44.83M |
| Net Income | -45.27M |
| EBITDA | -43.46M |
| EBIT | -44.25M |
| Loss Per Share | -0.85 |
Balance Sheet
The company has 81.51 million in cash and 13.79 million in debt, with a net cash position of 67.72 million or 0.97 per share.
| Cash & Cash Equivalents | 81.51M |
| Total Debt | 13.79M |
| Net Cash | 67.72M |
| Net Cash Per Share | 0.97 |
| Equity (Book Value) | 71.94M |
| Book Value Per Share | 1.03 |
| Working Capital | 80.13M |
Cash Flow
In the last 12 months, operating cash flow was -45.99 million and capital expenditures -593,000, giving a free cash flow of -46.58 million.
| Operating Cash Flow | -45.99M |
| Capital Expenditures | -593,000 |
| Depreciation & Amortization | 784,000 |
| Net Borrowing | -613,000 |
| Free Cash Flow | -46.58M |
| FCF Per Share | -0.67 |
Margins
| Gross Margin | 75.36% |
| Operating Margin | -525.44% |
| Pretax Margin | -532.35% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Onward Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.02% |
| Shareholder Yield | -8.02% |
| Earnings Yield | -22.49% |
| FCF Yield | -23.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Onward Medical is 9.24, which is 219.17% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 9.24 |
| Price Target Difference | 219.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 106.78% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Onward Medical has an Altman Z-Score of 0.35 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.35 |
| Piotroski F-Score | 3 |